CLINICAL TRIALS, STUDIES, REGISTRIES, DATA

OSE Immunotherapeutics Announces Publication of Preclinical Efficacy Results with Lusvertikimab in Acute Lymphoblastic Leukemia in the Journal ‘Blood’

Nicolas Poirier, Chief Executive Officer of OSE Immunotherapeutics, concludes: “We [...]

By |2024-07-01T06:45:36+00:00July 1, 2024|3rd Party Medical Device Industry News|Comments Off on OSE Immunotherapeutics Announces Publication of Preclinical Efficacy Results with Lusvertikimab in Acute Lymphoblastic Leukemia in the Journal ‘Blood’

PharmaEssentia Completes Patient Enrollment for Phase 2b EXCEED-ET Trial in Essential Thrombocythemia and Phase 3b ECLIPSE-PV Trial in Polycythemia Vera

“Myeloproliferative neoplasms, including ET and PV, are chronic blood diseases [...]

By |2024-06-25T17:02:37+00:00June 25, 2024|3rd Party Medical Device Industry News|Comments Off on PharmaEssentia Completes Patient Enrollment for Phase 2b EXCEED-ET Trial in Essential Thrombocythemia and Phase 3b ECLIPSE-PV Trial in Polycythemia Vera

Editas Medicine Reports New Safety and Efficacy Data from the RUBY Trial of Reni-cel in 18 Patients with Sickle Cell Disease | Presented at the European Hematology Association (EHA) Annual Congress

“These data confirm the observations from our prior clinical readouts [...]

By |2024-06-14T09:10:47+00:00June 14, 2024|3rd Party Medical Device Industry News|Comments Off on Editas Medicine Reports New Safety and Efficacy Data from the RUBY Trial of Reni-cel in 18 Patients with Sickle Cell Disease | Presented at the European Hematology Association (EHA) Annual Congress

Innovent Biologics Delivers Oral Presentation on Clinical Data of IBI363 (First-in-class PD-1/IL-2α-bias Bispecific Antibody Fusion Protein) in Advanced Non-small Cell Lung Cancer and Other Solid Tumors at the 2024 ESMO Virtual Plenary

Dr. Hui Zhou, Senior Vice President of Innovent, stated: “IBI363, [...]

By |2024-06-14T09:03:24+00:00June 14, 2024|3rd Party Medical Device Industry News|Comments Off on Innovent Biologics Delivers Oral Presentation on Clinical Data of IBI363 (First-in-class PD-1/IL-2α-bias Bispecific Antibody Fusion Protein) in Advanced Non-small Cell Lung Cancer and Other Solid Tumors at the 2024 ESMO Virtual Plenary
Go to Top